Remove 2026 Remove Biosimilars Remove Pharmaceutical Companies
article thumbnail

Construction starts on $400m biosimilars production centre in Slovenia

European Pharmaceutical Review

The first stage of construction has officially begun on Lek Pharmaceuticals’ new biologics and biosimilars production centre in Lendava, north eastern Slovenia. Sandoz is the parent company of Lek Pharmaceuticals , the oldest pharmaceutical company in Slovenia.

article thumbnail

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple β€œme-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

pharmaphorum

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. Sarah Rickwood has 30 years’ experience as a consultant to the pharmaceutical industry. appeared first on.

article thumbnail

Inflationary storm clouds will continue to buffet global pharma industry in 2023

Pharmaceutical Technology

This could evolve into pharmaceutical companies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles.

article thumbnail

Inflationary storm clouds will continue to buffet global pharma industry in 2023

Pharmaceutical Technology

This could evolve into pharmaceutical companies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles.